{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:46:36Z","timestamp":1787499996753,"version":"build-2736575974"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.psychres.2018.08.109","type":"journal-article","created":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T02:28:54Z","timestamp":1535682534000},"page":"481-493","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Evaluation of a few discrete clinical markers may predict categorization of actively symptomatic non-acute schizophrenia patients as treatment resistant or responders: A study by ROC curve analysis and multivariate analyses"],"prefix":"10.1016","volume":"269","author":[{"given":"Felice","family":"Iasevoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1157-4523","authenticated-orcid":false,"given":"Camilla","family":"Avagliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Altavilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2751-5683","authenticated-orcid":false,"given":"Annarita","family":"Barone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3563-2599","authenticated-orcid":false,"given":"Mariateresa","family":"Ciccarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8386-4132","authenticated-orcid":false,"given":"Luigi","family":"D'Ambrosio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7525-2024","authenticated-orcid":false,"given":"Danilo","family":"Notar Francesco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Razzino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Fornaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"de Bartolomeis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.psychres.2018.08.109_bib0001","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.2147\/NDT.S91170","article-title":"Neurological soft signs might be endophenotype candidates for patients with deficit syndrome schizophrenia","volume":"11","author":"Albayrak","year":"2015","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"2","key":"10.1016\/j.psychres.2018.08.109_bib0002","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10072-008-0866-9","article-title":"The brief assessment of cognition in schizophrenia. Normative data for the Italian population","volume":"29","author":"Anselmetti","year":"2008","journal-title":"Neurol. Sci."},{"issue":"9","key":"10.1016\/j.psychres.2018.08.109_bib0003","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1080\/17512433.2016.1200971","article-title":"Efficacy and safety of combining clozapine with electrical or magnetic brain stimulation in treatment-refractory schizophrenia","volume":"9","author":"Arumugham","year":"2016","journal-title":"Expert Rev. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.psychres.2018.08.109_bib0004","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1080\/00401706.1962.10490038","article-title":"Transformation of the independent variables","volume":"4","author":"Box","year":"1962","journal-title":"Technometrics"},{"issue":"2","key":"10.1016\/j.psychres.2018.08.109_bib0005","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1600-0447.2007.00992.x","article-title":"Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac","volume":"115","author":"Buckley","year":"2007","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.psychres.2018.08.109_bib0006","doi-asserted-by":"crossref","first-page":"11053","DOI":"10.1038\/srep11053","article-title":"Course of neurological soft signs in first-episode schizophrenia: relationship with negative symptoms and cognitive performances","volume":"5","author":"Chan","year":"2015","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.psychres.2018.08.109_bib0007","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1159\/000477313","article-title":"Antipsychotic-induced dopamine supersensitivity psychosis: pharmacology, criteria, and therapy","volume":"86","author":"Chouinard","year":"2017","journal-title":"Psychother. Psychosom."},{"issue":"11","key":"10.1016\/j.psychres.2018.08.109_bib0008","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S0006-3223(01)01271-9","article-title":"Management of treatment resistance in schizophrenia","volume":"50","author":"Conley","year":"2001","journal-title":"Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.psychres.2018.08.109_bib0009","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.psychres.2013.06.042","article-title":"Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: correlation with course of the illness, psychopathology, attitude to the treatment and antipsychotics doses","volume":"210","author":"de Bartolomeis","year":"2013","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.psychres.2018.08.109_bib0010","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.pnpbp.2017.09.002","article-title":"Treatment resistant schizophrenia and neurological soft signs may converge on the same pathology: evidence from explanatory analysis on clinical, psychopathological, and cognitive variables","volume":"81","author":"de Bartolomeis","year":"2018","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"5","key":"10.1016\/j.psychres.2018.08.109_bib0011","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.biopsych.2013.06.011","article-title":"Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function","volume":"75","author":"Demjaha","year":"2014","journal-title":"Biol. Psychiatry"},{"issue":"11","key":"10.1016\/j.psychres.2018.08.109_bib0012","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1017\/S0033291717000435","article-title":"Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors","volume":"47","author":"Demjaha","year":"2017","journal-title":"Psychol. Med."},{"issue":"2","key":"10.1016\/j.psychres.2018.08.109_bib0013","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1136\/eb-2014-101813","article-title":"Pharmacotherapy of treatment-resistant schizophrenia: a clinical perspective","volume":"17","author":"Dold","year":"2014","journal-title":"Evid. Based Ment. Health"},{"issue":"9","key":"10.1016\/j.psychres.2018.08.109_bib0014","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0149-2918(00)80082-X","article-title":"The effectiveness of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive to or unable to tolerate clozapine","volume":"22","author":"Dossenbach","year":"2000","journal-title":"Clin. Ther."},{"issue":"1","key":"10.1016\/j.psychres.2018.08.109_bib0015","doi-asserted-by":"crossref","first-page":"20","DOI":"10.4103\/0973-1229.91588","article-title":"Treatment-resistant schizophrenia: evidence-based strategies","volume":"10","author":"Englisch","year":"2012","journal-title":"Mens Sana Monogr."},{"issue":"10","key":"10.1016\/j.psychres.2018.08.109_bib0016","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.jpsychires.2013.06.013","article-title":"Decreased levels of D-aspartate and NMDA in the prefrontal cortex and striatum of patients with schizophrenia","volume":"47","author":"Errico","year":"2013","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.psychres.2018.08.109_bib0017","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.psychres.2015.11.028","article-title":"Profiling cognitive impairment in treatment-resistant schizophrenia patients","volume":"235","author":"Frydecka","year":"2016","journal-title":"Psychiatry Res."},{"issue":"4","key":"10.1016\/j.psychres.2018.08.109_bib0018","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/schbul\/sbu170","article-title":"Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials","volume":"41","author":"Fusar-Poli","year":"2015","journal-title":"Schizophr. Bull."},{"issue":"3","key":"10.1016\/j.psychres.2018.08.109_bib0019","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/wps.20167","article-title":"The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia","volume":"13","author":"Galderisi","year":"2014","journal-title":"World Psychiatry"},{"issue":"6","key":"10.1016\/j.psychres.2018.08.109_bib0020","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1176\/appi.ajp.2009.09060802","article-title":"International consensus study of antipsychotic dosing","volume":"167","author":"Gardner","year":"2010","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.psychres.2018.08.109_bib0021","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/schbul\/10.3.388","article-title":"The quality of life scale: an instrument for rating the schizophrenic deficit syndrome","volume":"10","author":"Heinrichs","year":"1984","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.psychres.2018.08.109_bib0022","series-title":"Applied Logistic Regression","author":"Hosmer","year":"2013"},{"issue":"3","key":"10.1016\/j.psychres.2018.08.109_bib0023","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1176\/appi.ajp.2016.16050503","article-title":"Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology","volume":"174","author":"Howes","year":"2017","journal-title":"Am. J. Psychiatry"},{"issue":"6","key":"10.1016\/j.psychres.2018.08.109_bib0024","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1192\/bjp.bp.111.105833","article-title":"Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation","volume":"201","author":"Howes","year":"2012","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.psychres.2018.08.109_bib0025","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.2147\/NDT.S47571","article-title":"Tobacco smoking in treatment-resistant schizophrenia patients is associated with impaired cognitive functioning, more severe negative symptoms, and poorer social adjustment","volume":"9","author":"Iasevoli","year":"2013","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.psychres.2018.08.109_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.schres.2018.06.030","article-title":"Clinical evaluation of functional capacity in treatment resistant schizophrenia patients: comparison and differences with non-resistant schizophrenia patients","author":"Iasevoli","year":"2018","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.psychres.2018.08.109_bib0027","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.psychres.2017.01.015","article-title":"Assessing patient-rated vs. clinician-rated adherence to the therapy in treatment resistant schizophrenia, schizophrenia responders, and non-schizophrenia patients","volume":"249","author":"Iasevoli","year":"2017","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.psychres.2018.08.109_bib0028","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.pnpbp.2015.08.010","article-title":"Treatment resistant schizophrenia is associated with the worst community functioning among severely-ill highly-disabling psychiatric conditions and is the most relevant predictor of poorer achievements in functional milestones","volume":"65","author":"Iasevoli","year":"2016","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"9","key":"10.1016\/j.psychres.2018.08.109_bib0029","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Arch. Gen. Psychiatry"},{"issue":"2","key":"10.1016\/j.psychres.2018.08.109_bib0030","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.psychres.2018.08.109_bib0031","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/YIC.0b013e32836508e6","article-title":"The social and economic burden of treatment-resistant schizophrenia: a systematic literature review","volume":"29","author":"Kennedy","year":"2014","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.psychres.2018.08.109_bib0032","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/j.2051-5545.2008.tb00181.x","article-title":"Deficit schizophrenia: an update","volume":"7","author":"Kirkpatrick","year":"2008","journal-title":"World Psychiatry"},{"key":"10.1016\/j.psychres.2018.08.109_bib0033","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1744-859X-9-24","article-title":"Predicting hospital admission and discharge with symptom or function scores in patients with schizophrenia: pooled analysis of a clinical trial extension","volume":"9","author":"Kozma","year":"2010","journal-title":"Ann. Gen. Psychiatry"},{"issue":"15","key":"10.1016\/j.psychres.2018.08.109_bib0034","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1017\/S0033291716002014","article-title":"Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses","volume":"46","author":"Lally","year":"2016","journal-title":"Psychol. Med."},{"issue":"1\u20133","key":"10.1016\/j.psychres.2018.08.109_bib0035","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.schres.2016.01.024","article-title":"Augmentation of clozapine with electroconvulsive therapy in treatment resistant schizophrenia: a systematic review and meta-analysis","volume":"171","author":"Lally","year":"2016","journal-title":"Schizophr. Res."},{"issue":"2 Suppl","key":"10.1016\/j.psychres.2018.08.109_bib0036","first-page":"S1","article-title":"Practice guideline for the treatment of patients with schizophrenia, second edition","volume":"161","author":"Lehman","year":"2004","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.psychres.2018.08.109_bib0037","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1176\/ajp.154.4.475","article-title":"Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance","volume":"154","author":"Meltzer","year":"1997","journal-title":"Am. J. Psychiatry"},{"issue":"6","key":"10.1016\/j.psychres.2018.08.109_bib0038","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/schbul\/sbt199","article-title":"Neurological soft signs predict abnormal cerebellar-thalamic tract development and negative symptoms in adolescents at high risk for psychosis: a longitudinal perspective","volume":"40","author":"Mittal","year":"2014","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.psychres.2018.08.109_bib0039","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpsychires.2014.07.001","article-title":"New therapeutic approaches for treatment-resistant schizophrenia: a look to the future","volume":"58","author":"Miyamoto","year":"2014","journal-title":"J. Psychiatr. Res."},{"issue":"4","key":"10.1016\/j.psychres.2018.08.109_bib0040","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1034\/j.1600-0447.2000.101004323.x","article-title":"Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning","volume":"101","author":"Morosini","year":"2000","journal-title":"Acta Psychiatr. Scand."},{"issue":"3","key":"10.1016\/j.psychres.2018.08.109_bib0041","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1093\/schbul\/sbv151","article-title":"Treatment-resistant schizophrenia patients show elevated anterior cingulate cortex glutamate compared to treatment-responsive","volume":"42","author":"Mouchlianitis","year":"2016","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.psychres.2018.08.109_bib0042","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.schres.2014.07.044","article-title":"The specific level of functioning scale: construct validity, internal consistency and factor structure in a large Italian sample of people with schizophrenia living in the community","volume":"159","author":"Mucci","year":"2014","journal-title":"Schizophr. Res."},{"issue":"Suppl 3","key":"10.1016\/j.psychres.2018.08.109_bib0043","first-page":"S133","article-title":"A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables","volume":"10","author":"Naber","year":"1995","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.psychres.2018.08.109_bib0044","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1097\/JCP.0b013e318267b3cd","article-title":"Predictors of clozapine response in patients with treatment-refractory schizophrenia: results from a Danish Register Study","volume":"32","author":"Nielsen","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.psychres.2018.08.109_bib0045","article-title":"Negative symptoms and reward disturbances in schizophrenia before and after antipsychotic monotherapy","author":"Nielsen","year":"2017","journal-title":"Clin. EEG Neurosci."},{"key":"10.1016\/j.psychres.2018.08.109_bib0046","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/1471-244X-11-113","article-title":"Is the PANSS used correctly? a systematic review","volume":"11","author":"Obermeier","year":"2011","journal-title":"BMC Psychiatry"},{"issue":"2","key":"10.1016\/j.psychres.2018.08.109_bib0047","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/oxfordjournals.schbul.a006870","article-title":"UCSD performance-based skills assessment: development of a new measure of everyday functioning for severely mentally ill adults","volume":"27","author":"Patterson","year":"2001","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.psychres.2018.08.109_bib0048","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jpsychires.2005.03.008","article-title":"Neurological soft signs, clinical symptoms and treatment reactivity in patients suffering from first episode schizophrenia","volume":"40","author":"Prikryl","year":"2006","journal-title":"J. Psychiatr. Res."},{"issue":"2","key":"10.1016\/j.psychres.2018.08.109_bib0049","first-page":"57","article-title":"Combined antipsychotics and electroconvulsive therapy in an acutely psychotic patient with treatment-resistant schizophrenia","volume":"47","author":"Rayikanti","year":"2017","journal-title":"Psychopharmacol. Bull."},{"issue":"12","key":"10.1016\/j.psychres.2018.08.109_bib0050","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJM199709183371202","article-title":"A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia","volume":"337","author":"Rosenheck","year":"1997","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.psychres.2018.08.109_bib0051","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/hup.1067","article-title":"Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder","volume":"24","author":"Rossi","year":"2009","journal-title":"Hum. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.psychres.2018.08.109_bib0052","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.pnpbp.2005.06.012","article-title":"Neurological soft signs and positive treatment response to olanzapine in chronic schizophrenia","volume":"30","author":"Sevincok","year":"2006","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2018.08.109_bib0053","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jpsychires.2013.12.007","article-title":"Are NMDA receptor antagonists beneficial in the treatment of schizophrenia","volume":"51","author":"Shim","year":"2014","journal-title":"J. Psychiatr. Res."},{"issue":"4","key":"10.1016\/j.psychres.2018.08.109_bib0054","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/oxfordjournals.schbul.a033421","article-title":"Nonresponding schizophrenia: differentiation by neurological soft signs and neuropsychological tests","volume":"25","author":"Smith","year":"1999","journal-title":"Schizophr. Bull."},{"issue":"2\u20133","key":"10.1016\/j.psychres.2018.08.109_bib0055","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.psychres.2015.02.021","article-title":"Dopamine supersensitivity psychosis as a pivotal factor in treatment-resistant schizophrenia","volume":"227","author":"Suzuki","year":"2015","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.psychres.2018.08.109_bib0056","series-title":"Using Multivariate Statistics","author":"Tabachnick","year":"2014"},{"issue":"5","key":"10.1016\/j.psychres.2018.08.109_bib0057","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/YIC.0000000000000086","article-title":"Delayed initiation of clozapine may be related to poor response in treatment-resistant schizophrenia","volume":"30","author":"Ucok","year":"2015","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.psychres.2018.08.109_bib0058","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s40261-013-0166-x","article-title":"Pathway to clozapine use: a comparison between a patient cohort from New Zealand and a cohort from the United Kingdom","volume":"34","author":"Wheeler","year":"2014","journal-title":"Clin. Drug Investig."},{"issue":"5","key":"10.1016\/j.psychres.2018.08.109_bib0059","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.4088\/JCP.16r10782","article-title":"Clozapine augmentation with antiepileptic drugs for treatment-resistant schizophrenia: a meta-analysis of randomized controlled trials","volume":"78","author":"Zheng","year":"2017","journal-title":"J. Clin. Psychiatry"}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178118300386?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178118300386?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,8]],"date-time":"2020-11-08T10:35:43Z","timestamp":1604831743000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178118300386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":59,"alternative-id":["S0165178118300386"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2018.08.109","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of a few discrete clinical markers may predict categorization of actively symptomatic non-acute schizophrenia patients as treatment resistant or responders: A study by ROC curve analysis and multivariate analyses","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2018.08.109","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}